Stock Research Monitor: AVXS, BHVN, and BMRN
LONDON, UK / ACCESSWIRE / May 9, 2018 / If you want a free Stock Review on BIIB sign up now at www.wallstequities.com/registration. On Tuesday, May 08, 2018, US markets saw four out of nine sectors finishing the day in green, four in red, and one in neutral territory. Major US indices were also mixed at the close of yesterday's session. The NASDAQ Composite ended the day at 7,266.90, up 0.02%; the Dow Jones Industrial Average edged 0.01% higher, to finish at 24,360.21; and the S&P 500 closed at 2,671.92, down 0.03%. This Wednesday morning, WallStEquities.com looks at the performance of these four Biotechnology stocks: AveXis Inc. (NASDAQ: AVXS), Biogen Inc. (NASDAQ: BIIB), Biohaven Pharmaceutical Holding Co. Ltd, (NYSE: BHVN) and BioMarin Pharmaceutical Inc. (NASDAQ: BMRN): All you have to do is sign up today for this free limited time offer by clicking the link below.
On Tuesday, shares in Bannockburn, Illinois headquartered AveXis Inc. recorded a trading volume of 941,320 shares, which was above their three months average volume of 884.73 thousand shares. The stock ended the session 0.05% higher at $217.51. The Company's shares have gained 88.91% over the previous three months and 181.89% in the past twelve months. The stock is trading above its 50-day and 200-day moving averages by 33.82% and 87.03%, respectively. Moreover, shares of AveXis, which engages in developing and commercializing treatments for patients suffering from rare and life-threatening neurological genetic diseases, have a Relative Strength Index (RSI) of 79.23. Get the full research report on AVXS for free by clicking below at:
Cambridge, Massachusetts headquartered Biogen Inc.'s stock closed the day 0.01% higher at $269.73 with a total trading volume of 1.25 million shares. The Company's shares have advanced 4.74% in the past month. The stock is trading below its 50-day moving average by 1.42%. Additionally, shares of Biogen, which discovers, develops, manufactures, and delivers therapies for the treatment of neurological and neurodegenerative diseases worldwide, have an RSI of 48.64.
On April 25th, 2018, research firm Robert W. Baird upgraded the Company's stock rating from ‘Neutral' to ‘Outperform'. Free research on BIIB can be accessed at:
Biohaven Pharmaceutical Holding
Shares in New Haven, Connecticut-based Biohaven Pharmaceutical Holding Co. Ltd recorded a trading volume of 192,388 shares. The stock ended yesterday's trading session 1.09% lower at $27.17. The Company's shares have advanced 11.63% in the past month and 40.05% in the past twelve months. The stock is trading below its 50-day moving average by 2.48%. Furthermore, shares of Biohaven Pharma, which develops product candidates to treat neurological diseases, including rare disorders, have an RSI of 46.75. Sign up today for the free research report on BHVN at:
San Rafael, California headquartered BioMarin Pharmaceutical Inc.'s stock finished Tuesday's session 0.18% lower at $86.81 with a total trading volume of 878,268 shares. The Company's shares have advanced 10.38% in the last month. The stock is trading above its 50-day and 200-day moving averages by 5.71% and 0.67%, respectively. Additionally, shares of BioMarin Pharma, which develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions, have an RSI of 59.23. Wall St. Equities' research coverage also includes the downloadable free report on BMRN at:
Wall St. Equities:
Wall St. Equities (WSE) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and micro-cap stocks. WSE has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below.
WSE has not been compensated; directly or indirectly; for producing or publishing this document.
PRESS RELEASE PROCEDURES:
The non-sponsored content contained herein has been prepared by a writer (the "Author") and is fact checked and reviewed by a third-party research service company (the "Reviewer") represented by a credentialed financial analyst [for further information on analyst credentials, please email firstname.lastname@example.org. Rohit Tuli, a CFA® charterholder (the "Sponsor"), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable-effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by WSE. WSE is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.
WSE, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. WSE, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, WSE, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.
NOT AN OFFERING
This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither WSE nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit
For any questions, inquiries, or comments reach out to us directly. If you're a company, we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at:
Phone number: 21 32 044 483
Office Address: 1 Scotts Road #24-10, Shaw Center Singapore 228
CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.
SOURCE: Wall St. Equities